News

A recent study reveals that one anti-VEGF treatment is more effective than another commonly used treatment.

The device is the size of a grain of rice and is refilled every six months.

Study results offer hope to patients with wet macular degeneration who are receiving anti-VEGF injections.

For patients suffering from age-related macular degeneration, gene therapy has the potential to transfigure the treatment options that are available.

The FDA just approved ranibizumab (Lucentis) as an ocular implant to be injected into the eye for people with wet macular degeneration, based upon the successful Archway study run under the FDA umb...

EyePoint Pharmaceuticals recently announced results of the Phase 1 clinical trial of their new wet age-related macular degeneration treatment, EYP-1901.

The new device offers a continuous therapeutic dose of ranibizumab to the eye in place of regular eye injections.

Researchers compared the visual outcomes and rate of intraoperative complications in patients with nAMD and control eyes that did not have nAMD that underwent phacoemulsification cataract surgery o...

There are five eye diseases that are the leading causes of blindness and low vision in the United States: age-related macular degeneration, cataracts, glaucoma, diabetic retinopathy and eye injurie...